Skip to Content
Merck
  • P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma.

P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2016-07-30)
Hui Pan, Hongyan Ni, LeiLei Zhang, Yue Xing, Jiayan Fan, Peng Li, Tianyuan Li, Renbing Jia, Shengfang Ge, He Zhang, Xianqun Fan
ABSTRACT

Uveal melanoma (UM) has a high mortality rate for primary intraocular tumors. Approximately half of UM patients present with untreatable and fatal metastases. Long non-coding RNAs (lncRNAs) have emerged as potent regulatory RNAs that play key roles in various cellular processes and tumorigenesis. However, to date, their roles in UM are not well-known. Here, we identified a transcriptional variant transcribed from the P2RX7 gene locus, named P2RX7-V3 (P2RX7 variant 3), which was expressed at a high level in UM cells. P2RX7-V3 silencing revealed that this variant acts as a necessary UM oncoRNA. Knockdown of P2RX7-V3 expression significantly suppressed tumor growth in vitro and in vivo. A genome-wide cDNA array revealed that a variety of genes were dysregulated following P2RX7-V3 silencing. These observations identified P2RX7-V3 that plays a crucial role in UM tumorigenesis and may serve as a useful biomarker in the diagnosis and prognosis treatment of UM in the future.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human P2RX7